Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross.
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic. The Danish drugmaker argues that the medications are too complex for those manufacturers to make safely.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.
Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and more.
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors.
Novo Nordisk: Time To Stay Calm Amid The Recent Plunge (Rating Upgrade)
Novo Nordisk faces growth deceleration concerns, intensified by competitive pressures from Eli Lilly and supply chain issues. NVO can improve buying sentiments by expanding its indications beyond its core weight loss and diabetes categories. NVO's growth-adjusted valuation has improved markedly, while its first-mover advantage should anchor its ability to scale profitably.
Novo Nordisk's oral diabetes drug cuts heart-related risks by 14% in study
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.
Ozempic, weight loss drugs found to cut substance abuse
Weight loss drugs such as Novo Nordisk (NYSE:NVO) AS' Ozempic have been found to cut alcohol and opioid abuse, according to a new study. Published in the journal Addiction, the study showed the rate of opioid overdoses among people taking GLP-1 drugs was 40% lower than those who were not.
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.
